HENRIQUE AYRES MAYRINK GIARDINI

Índice h a partir de 2011
4
Projetos de Pesquisa
Unidades Organizacionais
P ICHC, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

search.filters.applied.f.dateIssued: 2023 × Assunto: juvenile idiopathic arthritis ×

Resultados de Busca

Agora exibindo 1 - 4 de 4
  • article 3 Citação(ões) na Scopus
    The administration of methotrexate in patients with Still's disease, ""real-life"" findings from AIDA Network Still Disease Registry
    (2023) RUSCITTI, Piero; SOTA, Jurgen; VITALE, Antonio; LOPALCO, Giuseppe; IANNONE, Florenzo; MORRONE, Maria; GIARDINI, Henrique Ayres Mayrink; D'AGOSTIN, Marilia Ambuel; ANTONELLI, Isabelle Parente de Brito; ALMAGHLOUTH, Ibrahim; ASFINA, Kazi Nur; KHALIL, Najma; SFIKAKIS, Petros P.; LASKARI, Katerina; TEKTONIDOU, Maria; CICCIA, Francesco; IACONO, Daniela; RICCIO, Flavia; RAGAB, Gaafar; HUSSEIN, Mohamed A.; GOVONI, Marcello; RUFFILLI, Francesca; DIRESKENELI, Haner; ALIBAZ-ONER, Fatma; GIACOMELLI, Roberto; NAVARINI, Luca; BARTOLONI, Elena; RICCUCCI, Ilenia; MARTIN-NARES, Eduardo; TORRES-RUIZ, Jiram; CIPRIANI, Paola; COLA, Ilenia Di; HERNANDEZ-RODRIGUEZ, Jose; GOMEZ-CAVERZASCHI, Veronica; DAGNA, Lorenzo; TOMELLERI, Alessandro; MAKOWSKA, Joanna; BRZEZINSKA, Olga; IAGNOCCO, Annamaria; BELLIS, Elisa; CAGGIANO, Valeria; GAGGIANO, Carla; TARSIA, Maria; MORMILE, Ilaria; EMMI, Giacomo; SFRISO, Paolo; MONTI, Sara; ERTEN, Suekran; GIUDICE, Emanuela Del; LUBRANO, Riccardo; CONTI, Giovanni; OLIVIERI, Alma Nunzia; GULLO, Alberto Lo; THARWAT, Samar; KARAMANAKOS, Anastasios; GIDARO, Antonio; MAGGIO, Maria Cristina; TORRE, Francesco La; CARDINALE, Fabio; OGUNJIMI, Benson; MAIER, Armin; SEBASTIANI, Gian Domenico; OPRIS-BELINSKI, Daniela; FRASSI, Micol; VIAPIANA, Ombretta; BIZZI, Emanuele; CARUBBI, Francesco; FOTIS, Lampros; TUFAN, Abdurrahman; KARDAS, Riza Can; WIESIK-SZEWCZYK, Ewa; JAHNZ-ROZYK, Karina; FABIANI, Claudia; FREDIANI, Bruno; BALISTRERI, Alberto; RIGANTE, Donato; CANTARINI, Luca
    Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry.Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 & PLUSMN; 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy.Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.
  • article 1 Citação(ões) na Scopus
    Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's Disease
    (2023) VITALE, Antonio; CAGGIANO, Valeria; SFIKAKIS, Petros P.; DAGNA, Lorenzo; LOPALCO, Giuseppe; RAGAB, Gaafar; TORRE, Francesco La; ALMAGHLOUTH, Ibrahim A.; MAGGIO, Maria Cristina; SOTA, Jurgen; TUFAN, Abdurrahman; HINOJOSA-AZAOLA, Andrea; IANNONE, Florenzo; LOCONTE, Roberta; LASKARI, Katerina; DIRESKENELI, Haner; RUSCITTI, Piero; MORRONE, Maria; GIARDINI, Henrique A. Mayrink; PANAGIOTOPOULOS, Alexandros; COLA, Ilenia Di; MARTIN-NARES, Eduardo; MONTI, Sara; STEFANO, Ludovico De; KARDAS, Riza Can; DURAN, Rahime; CAMPOCHIARO, Corrado; TOMELLERI, Alessandro; ALABDULKAREEM, Abdulaziz Mohammed; GAGGIANO, Carla; TARSIA, Maria; BARTOLONI, Elena; ROMEO, Mery; HUSSEIN, Mohamed A.; LAYMOUNA, Ahmed Hatem; ANTONELLI, Isabele Parente de Brito; DAGOSTIN, Marilia Ambiel; FOTIS, Lampros; BINDOLI, Sara; NAVARINI, Luca; ALIBAZ-ONER, Fatma; SEVIK, Gizem; FRASSI, Micol; CICCIA, Francesco; IACONO, Daniela; CRISAFULLI, Francesca; PORTINCASA, Piero; JABER, Nour; KAWAKAMI-CAMPOS, Perla Ayumi; WIESIK-SZEWCZYK, Ewa; IAGNOCCO, Annamaria; SIMONINI, Gabriele; SFRISO, Paolo; BALISTRERI, Alberto; GIACOMELLI, Roberto; CONTI, Giovanni; FREDIANI, Bruno; FABIANI, Claudia; CANTARINI, Luca
    Introduction: The effectiveness of canakinumab may change according to the different times it is used after Still's disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment.Methods: Patients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still's disease. Seventy-seven (51 females and 26 males) patients with Still's disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent.Results: No statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response (p =0.62), partial response (p =0.61), treatment failure (p >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy (p =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use (p =0.34), daily glucocorticoid dosage (p =0.47), or concomitant methotrexate dosage (p =0.43) at the last assessment during CAN treatment.Conclusion: Canakinumab has proved to be effective in patients with Still's disease, regardless of its line of biologic treatment.
  • article 2 Citação(ões) na Scopus
    Still's disease continuum from childhood to elderly: data from the international AIDA Network Still's disease registry
    (2023) VITALE, Antonio; CAGGIANO, Valeria; LOPALCO, Giuseppe; GIARDINI, Henrique A. Mayrink; CICCIA, Francesco; ALMAGHLOUTH, Ibrahim A.; RUSCITTI, Piero; SFIKAKIS, Petros P.; TUFAN, Abdurrahman; DAGNA, Lorenzo; GIACOMELLI, Roberto; HINOJOSA-AZAOLA, Andrea; RAGAB, Gafaar; DIRESKENELI, Haner; FOTIS, Lampros; SOTA, Jurgen; IANNONE, Florenzo; MORRONE, Maria; ANTONELLI, Isabele Parente de Brito; DAGOSTIN, Marilia Ambiel; IACONO, Daniela; PATRONE, Martina; ASFINA, Kazi; ALANAZI, Fehaid; COLA, Ilenia Di; GAGGIANO, Carla; TEKTONIDOU, Maria G.; KARDAS, Riza Can; KUCUK, Hamit; CAMPOCHIARO, Corrado; TOMELLERI, Alessandro; NAVARINI, Luca; BERARDICURTI, Onorina; MARTIN-NARES, Eduardo; TORRES-RUIZ, Jiram; MAHMOUD, Ayman Abdel-Monem Ahmed; ALIBAZ-ONER, Fatma; KOURTESI, Katerina; TARSIA, Maria; SFRISO, Paolo; MAKOWSKA, Joanna; GOVONI, Marcello; TORRE, Francesco La; MAGGIO, Maria Cristina; MONTI, Sara; GIUDICE, Emanuela Del; EMMI, Giacomo; BARTOLONI, Elena; HERNANDEZ-RODRIGUEZ, Jose; GOMEZ-CAVERZASCHI, Veronica; MAIER, Armin; SIMONINI, Gabriele; IAGNOCCO, Annamaria; CONTI, Giovanni; OLIVIERI, Alma Nunzia; PAULIS, Amato De; GULLO, Alberto Lo; VIAPIANA, Ombretta; WIESIK-SZEWCZYK, Ewa; ERTEN, Sukran; OGUNJIMI, Benson; CARUBBI, Francesco; THARWAT, Samar; LASKARI, Katerina; COSTI, Stefania; TRIGGIANESE, Paola; KARAMANAKOS, Anastasios; CONFORTI, Alessandro; FRASSI, Micol; SEBASTIANI, Gian Domenico; GIDARO, Antonio; MAURO, Angela; BALISTRERI, Alberto; FABIANI, Claudia; FREDIANI, Bruno; CANTARINI, Luca
    Objective Still's disease is more frequently observed in the paediatric context, but a delayed onset is not exceptional both in the adulthood and in the elderly. However, whether paediatric-onset, adult-onset and elderly-onset Still's disease represent expressions of the same disease continuum or different clinical entities is still a matter of controversy. The aim of this study is to search for any differences in demographic, clinical features and response to treatment between pediatric-onset, adult-onset and elderly-onset Still's disease. Methods Subjects included in this study were drawn from the International AutoInflammatory Disease Alliance Network registry for patients with Still's disease. Results A total of 411 patients suffering from Still's disease were enrolled; the disease occurred in the childhood in 65 (15.8%) patients, in the adult 314 (76.4%) patients and in the elderly in 32 (7.8%) patients. No statistically significant differences at post-hoc analysis were observed in demographic features of the disease between pediatric-onset, adult-onset and elderly-onset Still's disease. The salmon-coloured skin rash (p=0.004), arthritis (p=0.009) and abdominal pain (p=0.007) resulted significantly more frequent among paediatric patients than in adult cases, while pleuritis (p=0.015) and arthralgia (p<0.0001) were significantly more frequent among elderly-onset patients compared with paediatric-onset subjects. Regarding laboratory data, thrombocytosis was significantly more frequent among paediatric patients onset compared with adult-onset subjects (p<0.0001), while thrombocytopenia was more frequent among elderly-onset patients although statistical significance was only bordered. No substantial differences were observed in the response to treatments. Conclusions Despite some minor difference between groups, overall, demographic, clinical, laboratory and treatments aspects of Still's disease were similarly observed in patients at all ages. This supports that pediatric-onset, adult-onset and elderly-onset Still's disease is the same clinical condition arising in different ages.
  • article 0 Citação(ões) na Scopus
    Clinical and laboratory features associated with macrophage activation syndrome in Still's disease: data from the international AIDA Network Still's Disease Registry
    (2023) TRIGGIANESE, Paola; VITALE, Antonio; LOPALCO, Giuseppe; GIARDINI, Henrique Ayres Mayrink; CICCIA, Francesco; AL-MAGHLOUTH, Ibrahim; RUSCITTI, Piero; SFIKAKIS, Petros Paul; IANNONE, Florenzo; ANTONELLI, Isabele Parente de Brito; PATRONE, Martina; ASFINA, Kazi Nur; COLA, Ilenia Di; LASKARI, Katerina; GAGGIANO, Carla; TUFAN, Abdurrahman; SFRISO, Paolo; DAGNA, Lorenzo; GIACOMELLI, Roberto; HINOJOSA-AZAOLA, Andrea; RAGAB, Gaafar; FOTIS, Lampros; DIRESKENELI, Haner; SPEDICATO, Veronica; DAGOSTIN, Marilia Ambiel; IACONO, Daniela; ALI, Hebatallah Hamed; CIPRIANI, Paola; SOTA, Jurgen; KARDAS, Riza Can; BINDOLI, Sara; CAMPOCHIARO, Corrado; NAVARINI, Luca; GENTILESCHI, Stefano; MARTIN-NARES, Eduardo; TORRES-RUIZ, Jiram; SAAD, Moustafa Ali; KOURTESI, Katerina; ALIBAZ-ONER, Fatma; SEVIK, Gizem; IAGNOCCO, Annamaria; MAKOWSKA, Joanna; GOVONI, Marcello; MONTI, Sara; MAGGIO, Maria Cristina; TORRE, Francesco La; GIUDICE, Emanuela Del; HERNANDEZ-RODRIGUEZ, Jose; BARTOLONI, Elena; EMMI, Giacomo; CHIMENTI, Maria Sole; MAIER, Armin; SIMONINI, Gabriele; CONTI, Giovanni; OLIVIERI, Alma Nunzia; TARSIA, Maria; PAULIS, Amato De; GULLO, Alberto Lo; WIESIK-SZEWCZYK, Ewa; VIAPIANA, Ombretta; OGUNJIMI, Benson; THARWAT, Samar; ERTEN, Sukran; NUZZOLESE, Rossana; KARAMANAKOS, Anastasios; FRASSI, Micol; CONFORTI, Alessandro; CAGGIANO, Valeria; MARINO, Achille; SEBASTIANI, Gian Domenico; GIDARO, Antonio; TOMBETTI, Enrico; CARUBBI, Francesco; RUBEGNI, Giovanni; CARTOCCI, Alessandra; BALISTRERI, Alberto; FABIANI, Claudia; FREDIANI, Bruno; CANTARINI, Luca
    To characterize clinical and laboratory signs of patients with Still's disease experiencing macrophage activation syndrome (MAS) and identify factors associated with MAS development. Patients with Still's disease classified according to internationally accepted criteria were enrolled in the AutoInflammatory Disease Alliance (AIDA) Still's Disease Registry. Clinical and laboratory features observed during the inflammatory attack complicated by MAS were included in univariate and multivariate logistic regression analysis to identify factors associated to MAS development. A total of 414 patients with Still's disease were included; 39 (9.4%) of them developed MAS during clinical history. At univariate analyses, the following variables were significantly associated with MAS: classification of arthritis based on the number of joints involved (p = 0.003), liver involvement (p = 0.04), hepatomegaly (p = 0.02), hepatic failure (p = 0.01), axillary lymphadenopathy (p = 0.04), pneumonia (p = 0.03), acute respiratory distress syndrome (p < 0.001), platelet abnormalities (p < 0.001), high serum ferritin levels (p = 0.009), abnormal liver function tests (p = 0.009), hypoalbuminemia (p = 0.002), increased LDH (p = 0.001), and LDH serum levels (p < 0.001). At multivariate analysis, hepatomegaly (OR 8.7, 95% CI 1.9-52.6, p = 0.007) and monoarthritis (OR 15.8, 95% CI 2.9-97.1, p = 0.001), were directly associated with MAS, while the decade of life at Still's disease onset (OR 0.6, 95% CI 0.4-0.9, p = 0.045), a normal platelet count (OR 0.1, 95% CI 0.01-0.8, p = 0.034) or thrombocytosis (OR 0.01, 95% CI 0.0-0.2, p = 0.008) resulted to be protective. Clinical and laboratory factors associated with MAS development have been identified in a large cohort of patients based on real-life data.